Body iron stores and the risk of type 2 diabetes in middle-aged men

We investigated the risk of type 2 diabetes mellitus (T2DM) over a wide range of body iron stores.

Prospective cohort of 1613 men in the Kuopio Ischemic Heart Disease Risk Factor study, aged 42-60 years, free of T2DM and hereditary hemochromatosis at baseline in 1984-1989. Baseline serum ferritin (sF) and serum-soluble transferrin receptor (sTfR) concentrations were used to predict incident T2DM. T2DM was assessed by questionnaires, blood glucose measurements, and medication reimbursement register.

There were 331 cases of incident T2DM during the mean follow-up of 16.8 years (27,098 person-years). At baseline, subjects who later developed T2DM had average sF concentrations of 191 μg/l (S.D. 155) vs 151 μg/l (S.D. 119) among those who remained healthy, P<0.001. In a multivariate-adjusted logistic regression, each 100 μg/l increase in sF corresponded to an average of 14% increased (odds ratio=1.14, 95% CI 1.03-1.26, P=0.009) risk of developing T2DM. In a Cox regression, a markedly increased risk of developing T2DM was observed from the fourth sF quintile (185 μg/l, the median) upward (hazard ratio (HR) first vs fifth quintile=1.5, 95% CI 1.0-2.2, P-trend=0.05). In a corresponding Cox model in sTfR, the subjects in the third quintile (1840 μg/l, the median) had the least risk (HR=0.63, 95% CI 0.42-0.97, P=0.04).

Body iron within the sF reference range is not an important determinant of T2DM risk, whereas high normal and above is associated with markedly increased risk. Iron depletion toward iron deficiency as assessed by sTfR is not protective against T2DM. A rule of thumb safe range could be 30-200 μg/l of sF.